Azenta, Inc. (AZTA)

Over the past six months, Azenta's stock price has experienced significant volatility. As of February 2026, the stock has declined by approximately 30% over the last year. A notable event was the post-earnings sell-off on February 4, 2026, which saw shares tumble nearly 20% following the release of Q1 2026 results, where the company reported a Q1 2026 non-GAAP EPS of $0.09, missing the consensus estimate of $0.14. Conversely, in November 2024, Azenta's shares surged over 30% due to its inclusion in the S&P 600 and an analyst upgrade. On December 23, 2025, Azenta announced a definitive agreement for the sale of its B Medical Systems business, a transaction expected to close by March 31, 2026.

The provided information does not explicitly detail demand seasonality for Azenta, Inc.'s products and services. However, it indicates that the company has struggled to consistently generate demand over the last five years, with sales dropping at an annualized rate of 2.3%. Despite these trends, sell-side analysts anticipate revenue growth of 5.4% over the next 12 months, suggesting an expected improvement in demand for its newer products and services.

Azenta, Inc. is a life sciences technology company specializing in biological and chemical sample exploration and management solutions, operating within the Healthcare sector. The company's business is divided into Sample Management Solutions (SMS) and Multiomics (GENEWIZ). The SMS segment offers products and services, including Sample Repository Services (SRS), automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices. The Multiomics segment, operating under the GENEWIZ brand, provides genomic analysis services, including Next-Generation Sequencing and Gene Synthesis. Azenta aims to be a key steward of the world's biological samples, aligning with the future of precision medicine.

Azenta, Inc. maintains a global presence with operations in North America, Europe, and Asia. The company's headquarters are located in Burlington, Massachusetts, U.S. A significant portion of its revenue is generated in the United States, and it also operates in China, the United Kingdom, and other parts of Europe.

In March 2025, Azenta published its 2024 Environmental, Social, & Governance (ESG) Report, highlighting its commitment to sustainable procurement and expanding its partnership with EcoVadis® to evaluate the ESG performance of its suppliers. While the company has faced financial challenges and stock declines, there is no specific information detailing events that negatively impacted its general brand reputation (beyond financial performance) in the past year.

Institutional investors hold a substantial majority of Azenta's shares. Major institutional owners include BlackRock, Inc. (holding approximately 15.01% as of September 30, 2025), Politan Capital Management, L.P. (10.04%), The Vanguard Group, Inc. (9.65%), Dimensional Fund Advisors LP (4.57%), and State Street Global Advisors, Inc. (3.72%). Insider ownership, representing executive officers and board members, is a modest 1.8%.